Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02958969 · ADVERSE EVENTS

Adverse events

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma · Source last updated 2019-12-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
1 year
Other-event reporting threshold
5%
Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Apixaban

apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months Apixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months

0 / 503 / 500 / 50

Group identifiers: EG000: Apixaban

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    1. assessment Type
      SYSTEMATIC_ASSESSMENT
      organ System
      Blood and lymphatic system disorders
      stats
      1. group Id
        EG000
        num Affected
        3
        num At Risk
        50
        num Events
        3
      term
      non-major bleeding
    Complete source fields
    event Groups
    1. deaths Num Affected
      0
      deaths Num At Risk
      50
      description
      apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months Apixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
      id
      EG000
      other Num Affected
      3
      other Num At Risk
      50
      serious Num Affected
      0
      serious Num At Risk
      50
      title
      Apixaban
    frequency Threshold
    5
    other Events
    1. assessment Type
      SYSTEMATIC_ASSESSMENT
      organ System
      Blood and lymphatic system disorders
      stats
      1. group Id
        EG000
        num Affected
        3
        num At Risk
        50
        num Events
        3
      term
      non-major bleeding
    time Frame
    1 year

    Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

    Preserved source evidence · Not medical advice